"Ozempic Eats Your Muscle" — Here's What the Research on GLP-1 Drugs Actually Shows
If you've spent any time on Instagram or TikTok in the last year, you've probably seen it: someone warning that GLP-1 drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound, Mounjaro) don't just melt fat — they melt muscle right along with it, leaving people "skinny fat" underneath their smaller clothing size. For women over 40 who are already fighting to hold onto muscle through perimenopause and beyond, that's not a cosmetic worry — it's a real question about strength, metabolism, and independence down the road.
What they're saying:
The claim often goes like this: GLP-1 receptor agonists suppress appetite so aggressively that the body loses lean tissue — muscle, not just fat — right alongside the pounds on the scale, and that this muscle loss is a hidden cost nobody warns you about before you start the medication.
What the evidence actually shows:
This one isn't a myth to bust — the concern is real, but the size of it depends heavily on details that rarely make it into a viral clip. A 2026 review focused specifically on older women found that roughly 25-40% of total weight lost on GLP-1 receptor agonists is lean mass, including muscle — with women 65 and older in clinical trials losing 10-20% of body weight overall, and tirzepatide (Zepbound, Mounjaro) producing the larger losses at 15-21% (Moscucci et al., Nutrients, 2026). However, that 25-40% range isn't unique to these drugs — any significant weight loss, from dieting alone to bariatric surgery, causes a loss in lean muscle mass in addition to fat mass. The truth is that the range is wide, and where an individual lands within it depends on many factors, such as age, starting muscle mass, protein intake, and whether resistance training is part of the picture.
A protocol paper for an ongoing randomized controlled trial (the LEAN-PREP study) cites data showing the lean-mass share of total weight loss on tirzepatide and similar drugs ranges from 15% up to 50%, and notes that in one 28-week trial of tirzepatide in people with type 2 diabetes, an average 11.2 kg of weight lost included 1.6 kg of fat-free mass — this was a much smaller share than the more alarming headlines suggest (Alawadhi et al., BMJ Open, 2026). That trial is specifically testing whether adding structured resistance exercise and higher protein intake, alone or combined, changes that ratio — using MRI-measured thigh muscle size as its primary outcome, which tells you researchers now consider this important enough to test directly rather than debate anecdotally.
It's also worth pausing on a distinction that gets flattened in most social media takes: muscle mass and muscle strength don't necessarily move together. A 2026 review found that in shorter trials, handgrip strength held up reasonably well even as lean tissue declined — but longer-term and retrospective data in older adults told a different story, with reports of declining handgrip strength and accelerated sarcopenia risk after prolonged semaglutide use, meaning lean tissue loss on a scan isn't a reliable stand-in for how strong someone actually stays (Prokopidis, British Journal of Pharmacology, 2026). And a separate 2025 analysis raised a related concern for the other end of treatment: after stopping a GLP-1 drug, weight regain tends to be lopsided toward fat rather than muscle — one dataset on liraglutide discontinuation showed roughly 2.5 kg of lean mass regained against 6.3 kg of fat mass, which over repeated cycles of starting and stopping could gradually shift someone's body composition in the wrong direction even if their weight on the scale looks stable (Prokopidis, Daly & Suetta, Journal of Nutrition, Health & Aging, 2025).
What this means for you:
If you're over 40 and considering or already using a GLP-1 medication, the muscle-loss concern is legitimate — but it's also one of the more modifiable risks in this whole conversation, not an inevitable side effect you just have to accept. This matters more for women in this age group specifically, since natural muscle loss from declining estrogen is already underway before any medication enters the picture — stacking a second source of lean-tissue loss on top of that makes the specifics below a genuine priority. The research doesn't just say "lift weights and eat protein" in the abstract — several of the actual trials get precise about what that looks like.
What the resistance training actually looks like: a 2025 review of exercise guidance for people on GLP-1 medications lays out a practical framework: 2-3 resistance sessions per week, 20-30 minutes each, for a weekly total of roughly 60-90 minutes, using whatever's accessible — resistance bands, dumbbells, machines, or bodyweight (Codella, Senesi & Luzi, Frontiers in Clinical Diabetes and Healthcare, 2025). The LEAN-PREP trial's home-based protocol is more specific still: three sessions a week built around seven exercises covering the major muscle groups — squats, lunges, planks, band rows, band lateral raises, press-ups, and calf raises — starting at a single set per exercise at a moderate effort level in week one, adding a second set by week five and a third by week ten, all at a level that should feel genuinely challenging by the final few reps, with participants moving to harder variations of an exercise once 20 clean reps become achievable (Alawadhi et al., BMJ Open, 2026). The specific numbers matter less than the pattern: consistency (2-3x weekly), effort that actually challenges you rather than a token set of light reps, and progression over time — adding a set, a rep, or a harder variation every few weeks — rather than repeating the same easy routine indefinitely. This is where an experienced trainer can really help with the programming, making sure your body can handle the added load while keeping injury risk low.
What the protein amount actually needs to be: the source of your protein matters less than most people assume, but leucine content matters greatly. In a trial of obese older adults combining a reduced-calorie diet with resistance training, one group took a daily supplement of about 21 grams of whey protein, 2.8 grams of leucine, and 800 IU of vitamin D — taken after breakfast and after each workout — while the other took a placebo; over 13 weeks, the supplemented group gained a small amount of muscle mass while the placebo group lost muscle, a meaningful difference (Verreijen et al., American Journal of Clinical Nutrition, 2015). That's real evidence for a specific protein strategy, but it doesn't mean it has to come from a tub of powder. A separate trial comparing a plant-based protein blend, the same blend with added leucine, and whey protein found the plain plant blend triggered less of a muscle-building response than whey — but once its leucine content was boosted to match whey's (roughly 3 grams), it performed just as well (Lim, Janssen, Currier et al., Current Developments in Nutrition, 2024). This is great news for anyone cutting back on red meat or eating a vegetarian or vegan diet. Worth noting, though: that trial was done in healthy young adults, not the population this post is about — but the underlying leucine-threshold finding lines up with older research in this space and is generally treated as applying across ages. In practical terms, that means chicken breast, salmon, eggs, Greek yogurt, and lentils can all get the job done, as long as a given meal has enough total protein and leucine in it — for most adults, that's somewhere around 25-30 grams of protein per meal, spread across three to four meals a day rather than backloaded into dinner. Protein powder isn't a requirement; it's a convenience tool for hitting that per-meal target on days when the medication has suppressed appetite enough that a full chicken breast feels like too much — which, for many people on these drugs, is often.
Tracking more than the number on the scale — things like grip strength, how your working weights feel, how stairs feel — gives you a better read on what's actually happening to your body than weight alone ever will.
Bottom line for your training this week: if you're on or considering a GLP-1 medication, treat resistance training as part of the protocol, not an afterthought to it — two to three sessions a week with adequate protein is the one intervention the research keeps coming back to for protecting the muscle you have while the number on the scale drops. If you're not sure how to structure that around your current program, dose, and goals, that's exactly the kind of thing worth mapping out properly with an experienced trainer rather than guessing at.
## References
- Moscucci F, et al. A Narrative Review on GLP-1 Receptor Agonists for Obesity in Older Women: Maximizing Weight Loss While Preserving Lean Mass. Nutrients. 2026;18(4):632.
- Alawadhi AA, et al. LEAN mass Preservation with Resistance Exercise and Protein during semaglutide and tirzepatide therapy (LEAN-PREP study): a protocol for a randomised controlled trial. BMJ Open. 2026.
- Prokopidis K. Glucagon-like peptide-1 receptor agonists and muscle strength changes in older adults: Risks beyond muscle mass reductions. British Journal of Pharmacology. 2026.
- Prokopidis K, Daly RM, Suetta C. Weighing the risk of GLP-1 treatment in older adults: Should we be concerned about sarcopenic obesity? Journal of Nutrition, Health & Aging. 2025. doi:10.1016/j.jnha.2025.100652.
- Codella R, Senesi P, Luzi L. Exercise prescription for people using GLP-1 receptor agonists. Frontiers in Clinical Diabetes and Healthcare. 2025.
- Verreijen AM, Verlaan S, Engberink MF, Swinkels S, de Vogel-van den Bosch J, Weijs PJM. A high whey protein-, leucine-, and vitamin D-enriched supplement preserves muscle mass during intentional weight loss in obese older adults: a double-blind randomized controlled trial. American Journal of Clinical Nutrition. 2015;101(2):279-286.
- Lim C, Janssen TAH, Currier BS, et al. Muscle protein synthesis in response to plant-based protein isolates with and without added leucine versus whey protein in young men and women. Current Developments in Nutrition. 2024.
This article summarizes peer-reviewed research and does not constitute medical advice. Anyone taking or considering a GLP-1 receptor agonist should discuss muscle preservation strategies, protein needs, and exercise programming with their prescribing physician and a qualified trainer.
